胃轻瘫病程或病因与经口内镜下幽门肌切开术后临床应答的关联
单中心回顾性纵向研究纳入40例难治性胃轻瘫患者(非糖尿病25例、糖尿病15例),评估经口内镜下幽门肌切开术的安全性和疗效。术后胃轻瘫主要症状指数(GCSI)显著改善,恶心/呕吐亚量表持续改善至18个月,胃排空显像滞留率降低41.7%;病程较长与12个月GCSI改善较差相关,病因与临床改善无关。
要点
- GPOEM术后GCSI显著改善(F[2.176, 17.405]=10.152,P=.001),恶心/呕吐亚量表持续改善至18个月。
- 胃排空显像滞留率显著降低41.7%(t=-7.90;P<.00001),腹胀无显著改善(P=.236)。
- 病程较长与12个月GCSI改善较差相关(P=.02),病因与临床改善无关(P=.16)。
核心结论
- GPOEM似乎是治疗难治性胃轻瘫安全有效的微创疗法,尤其适用于以恶心/呕吐为主且病程较短的患者,与病因无关。
- 作者提出接受GPOEM的临床标准应为GCSI至少2.0且胃滞留大于20%。
研究设计与样本
- 单中心回顾性纵向研究,在一家三级医院进行,为期18个月。
- 纳入40例难治性胃轻瘫患者,其中非糖尿病25例、糖尿病15例。
主要发现
- GCSI在研究期间显著改善(F[2.176, 17.405]=10.152,P=.001)。
- 恶心/呕吐亚量表持续改善至18个月(F[2.213, 17.704]=15.863,P<.00001)。
- 腹胀无显著改善(F[2.099, 16.791]=1.576,P=.236)。
- 胃排空显像滞留率显著降低41.7%(t=-7.90;P<.00001)。
- 多变量线性回归显示病程与12个月GCSI改善显著相关(P=.02),病程较长与较差的长期应答相关;病因与临床改善无关(P=.16)。
关键数值与推荐
- 作者提出接受GPOEM的临床标准应为GCSI至少2.0且胃滞留大于20%。
临床怎么用
- 作者认为GPOEM似乎是治疗难治性胃轻瘫安全有效的微创疗法,尤其适用于以恶心/呕吐为主且病程较短的患者,与病因无关。
- 作者提出接受GPOEM的临床标准应为GCSI至少2.0且胃滞留大于20%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Gastric per-oral endoscopic pyloromyotomy (GPOEM) is a novel procedure with promising potential for the treatment of gastroparesis but with limited data regarding predictors of clinical response. This study aims to evaluate the safety and efficacy of the procedure and explore the impact of duration and etiology (diabetic vs nondiabetic) of gastroparesis on clinical outcome as measured by the Gastroparesis Cardinal Symptom Index (GCSI). METHODS: A single-center retrospective longitudinal study at a tertiary care hospital was performed over an 18-month period. Forty patients with refractory gastroparesis (25 nondiabetic and 15 diabetic patients) were included. RESULTS: GCSI significantly improved throughout the study period (F[2.176, 17.405] = 10.152, P = .001). The nausea/vomiting subscale showed sustained improvement through 18 months (F[2.213, 17.704] = 15.863, P < .00001). There was no significant improvement in bloating (F[2.099, 16.791] = 1.576, P = .236). Gastric scintigraphy retention was significantly reduced by 41.7% (t = -7.90; P < .00001). Multivariate linear regression modeling revealed a significant correlation between the duration of disease and a GCSI improvement at 12 months (P = .02), with a longer duration of disease associated with a poorer long-term response. The etiology of gastroparesis was not associated with clinical improvement (P = .16). Adverse events (7.5%) included 1 capnoperitoneum, 1 periprocedure chronic obstructive pulmonary disease exacerbation, and 1 mucosotomy closure site disruption. CONCLUSIONS: GPOEM appears to be a safe and effective minimally invasive therapy for refractory gastroparesis, especially for patients with predominant nausea/vomiting and shorter duration of disease, regardless of the etiology. We propose the clinical criteria for undergoing GPOEM should be a GCSI of at least 2.0 and a gastric retention of greater than 20%.
引用
- Mekaroonkamol P, Patel V, Shah R, et al. Association between duration or etiology of gastroparesis and clinical response after gastric per-oral endoscopic pyloromyotomy. Gastrointest Endosc. 2019. PMID: 30653937. doi:10.1016/j.gie.2018.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。